Thursday, March 28

Pfizer wants to produce a vaccine against pneumococcal infection in Kazakhstan

Google+ Pinterest LinkedIn Tumblr +

In accordance with the Memorandum of Cooperation signed with Pfizer during the visit of President of Kazakhstan Kassym-Jomart Tokayev to New York in September 2022, Deputy Prime Minister – Minister of Foreign Affairs of the Republic of Kazakhstan Mukhtar Tleuberdi held talks with a delegation of Pfizer headed by the Regional Director for Europe, Asia and Africa by Ozgur Yaziyurt. The meeting was also attended by Minister of Health of the Republic of Kazakhstan Azhar Giniyat and Chairman of the Board of SK-Pharmacy LLP Yerkhat Iskaliyev.

The parties discussed topical issues of expanding the presence of the American company in Kazakhstan, including localization of contract production of the pneumococcal vaccine “Preventar-13”. The American side was informed about efforts to improve legislation to attract biopharmaceutical TNCs to the Kazakh market. In turn, Pfizer positively noted the efforts and changes in the regulatory legal acts of the Republic of Kazakhstan regulating pharmaceutical activities.

The American multinational company Pfizer, headquartered in New York, is one of the world leaders in the biopharmaceutical market. Pfizer’s main research center is located in Groton, Connecticut.

Today, the company is engaged in the creation of medicines for diseases of the cardiovascular system, musculoskeletal system, produces antibiotics, viagra, immunosuppressants and more. In 2020, BioNTech, Pfizer and Fosun Pharma developed a coronavirus vaccine.

Source: Press Center of the Ministry of Foreign Affairs of the Republic of Kazakhstan

Share.

Comments are closed.